We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK
Porton Down, UK; 16 April 2012: GW Pharmaceuticals plc (AIM: GWP) confirms that it has now earned the €11.9 million milestone payment due as a result of the recently amended terms of its licence agreement with Almirall S.A. (announced on 15 March 2012).
Professor Vincenzo Di Marzo to direct GW’s global pre-clinical research programme Porton Down, UK; 8 March 2012: GW Pharmaceuticals plc (AIM: GWP) today announces that, effective March 1st 2012, Professor Vincenzo Di Marzo has agreed to direct GW’s global pre-clinical research programme and will
Sativex regulatory approval received in Austria Porton Down, UK; 7 February 2012: GW Pharmaceuticals plc (AIM: GWP) today announces a regulatory update for Sativex® (Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) oromucosal spray. Sativex ® has received regulatory approval in Austria as a
